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Salivaa b s t r a c t
Studies have suggested PTSD to be associated with an inflammatory state, although few studies have
examined the balances between stimulatory and inhibitory immune mediators in PTSD. An exploratory
approach was taken to assess the immune imbalances between Th1 stimulatory, inflammatory and
inhibitory mediators associated with PTSD. This approach focused on a tightly-controlled and relatively
homogeneous population of Veterans, all with similar levels of combat exposure in the Afghanistan and
Iraq wars, but some testing negative and others testing positive for PTSD. Although the sample size was
small (6 controls and 7 with PTSD) and a limitation of this study, the results showed significant imbal-
ances in immune cytokines favoring a Th1 and inflammatory state, with reduced levels of inhibitory
cytokines in Veterans with PTSD. This was particularly prominent in the saliva of PTSD subjects compared
to in their plasma.
Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
Over 2.5 million U.S. service members have been deployed to
Operation Iraq Freedom/Operation Enduring Freedom (OEF/OIF)
arenas since 2001. An unprecedented proportion of these service
members develop post-traumatic stress disorder (PTSD) following
combat exposure in Afghanistan and Iraq [1,2]. According to
reports from the Department of Veterans Affairs, 15.7% of these
OEF/OIF Veterans have PTSD [1]. PTSD is not limited to combat
but is also seen following natural disasters, sexual trauma or loss
of family members [3,4]. Therefore, PTSD has a tremendous
economic and social impact on the community at large. In the past
decade, extensive research has been devoted to identify the biolog-
ical causes of PTSD. However, the precise mechanisms of pathogen-
esis of PTSD remain unclear.
Studies involving human subjects with PTSD have shown corre-
lations between inflammation and PTSD following trauma expo-
sure, though it is unlikely that inflammation is the primary cause
of PTSD. These measurements of the various immune mediators
in PTSD subjects have been somewhat haphazard, but collectivelythe results of these studies have suggested immune alterations
toward increased levels of inflammatory cytokines [4–8]. Studies
have also shown increased levels of inflammatory mediators in
saliva following stress exposure, although such studies of salivary
cytokine levels are relatively few [3,9]. A study of hospitalized
patients with traumatic orthopedic injuries showed that those
who developed PTSD had increased blood levels of inflammatory
mediators and reduced inhibitory mediators, and suggested that
this could be used as a biomarker for PTSD [7]. A prospective study
of deployed Marines showed that pre-deployment levels of
C-reactive protein, an indicator of inflammation, predicted post-
deployment PTSD and suggested inflammation to be a contributor
to PTSD [10].
Studies using animal models for PTSD have been more compre-
hensive and definitive than studies with PTSD in human subjects.
Animal models of PTSD have shown peripheral inflammation
triggering neuroinflammation in the CNS [11–13], dependence on
immune function for anxiety behavior following stress sensitiza-
tion [14,15], and the tempering of maladaptation to acute psycho-
logical stress by neutralizing the inflammatory cytokine IL1 [16] or
by treatment with immune inhibitory Treg cells [17]. Induction of
peripheral inflammation in animal models causes an increase in
activation of brain microglia and in levels of inflammatory media-
tors in the hippocampus [13]. Studies with stress-sensitized mice
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the brain re-established anxiety [14]. Analyses of aggressor-
exposed mice that were subjected to trauma reminders showed
increased immune inflammatory signaling pathways in both the
periphery and neuroinflammation in the CNS of this PTSD model
[18,19].
Most studies assessing the immune linkagewith PTSD have been
hampered by the variability in the type and severity of trauma expo-
sure that led to PTSD. We conducted an exploratory study in which
levels of stimulatory as well as inhibitory cytokines were measured
in a limited, but a tightly-controlled and relatively homogeneous
population of OEF/OIF Veterans, all with similar levels of combat
exposure, but some testing negative and others testing positive for
PTSD. The results of this study showed an imbalance in immune
cytokines favoring a Th1 and inflammatory state,with reduced inhi-
bitory cytokines. This was particularly prominent in the saliva of
PTSD subjects compared to in their plasma.2. Methods
2.1. Research participants
All the subjects participating in this study were OEF/OIF Veter-
ans that were recruited through the local VA Medical Center, either
through the OEF/OIF program or upon referral by the OEF/OIF Pro-
gram to the PTSD clinic. The research protocol of this study was
approved by the Institutional Review Boards (IRB) of the Medical
University of South Carolina, which is the IRB of record for the
Ralph H. Johnson VA Medical Center. The brief description and vol-
untary nature of this study were explained to participants by a
trained research assistant, and those who were interested in par-
ticipating in this research were screened to determine eligibility
for study involvement with inclusion and exclusion criteria
described below. Written informed consent was obtained from
all of the participants before the formal interview.2.2. Procedure
After collecting the demographic and deployment information,
participants were assessed by a trained research assistant for the
presence of PTSD or other psychiatric disorders with Mini-
International Neuropsychiatric Interview (MINI) [20]. MINI is valid
and reliable structured diagnostic instruments that assess the pres-
ence of DSM-IV diagnoses. A board-certified psychiatrist (ZW)
interviewed participants for combat exposure history and PTSD
status, as well as other major psychiatric illnesses that would be
exclusionary (see inclusion/exclusion section below). Therefore,
full diagnostic level data and demographic data are available for
all 13 participants. All participants provided a peripheral blood
and saliva sample via standard methods.
All research participants completed the Combat Exposure Scale
(CES) [21], a 7-item self-report measure, used to obtain informa-
tion regarding exposure to wartime stressor events. The measure
has total scores ranging from 1 to 41, with a higher number reflect-
ing a higher severity of combat exposure. These participants also
were interviewed using the Clinician Administered PTSD Scale
(CAPS) [22], a diagnostic interview for current and lifetime PTSD.
The CAPS has been used in over 200 studies and has excellent psy-
chometric properties. The CAPS demonstrates high inter-rater reli-
ability (i.e., above 0.86) and internal consistency on each of the
three PTSD symptom clusters (range 0.63 to 0.89), and correlates
strongly (i.e., above 0.61) with other measures of PTSD [23,24].
Developed by researchers at the National Center of PTSD, this
structured interview assesses all 17 symptoms of PTSD for fre-
quency (scored on a 0 [never] to 4 [daily or almost every day])and intensity (0 [none] to 4 [extreme, incapacitating distress]). This
measure also assesses subjective distress, functional impairment,
and onset and duration of symptoms, and includes response valid-
ity items. In addition, the Hamilton Depression (Ham-D) Scale [25]
was used to for assess the symptom severity of depression.
Inclusion criteria for enrollment into the research study were:
combat Veterans of the OEF/OIF arenas, male or female, age 25–
55 with good physical health, evidence of combat as defined by a
history of deployment to a combat zone (a DD214) and trauma
exposure sufficient to meet Category A of PTSD criteria [26]. The
study allowed participation of subjects with depressive disorders,
but only if the depressive episodes were secondary to PTSD; sub-
jects with prior episodes of depression were excluded from this
study. Exclusion criteria were age younger than 25 or greater than
55, an active or lifetime major mental health diagnosis as deter-
mined by DSM-IV Axis I Disorders, major traumatic brain injury,
current substance dependence and abuse within 6 months, females
who are pregnant or likely to become pregnant, active suicidal
thoughts and behavior, conditions known to prominently impact
on immune reactivity such as recent chemotherapy or HIV. Using
the method of extreme discordant phenotype (EDP) [27], only dis-
tinct phenotypes were enrolled into either Group I (PTSD) or Group
II (controls), based on diagnosis via the CAPS-IV scores. Therefore,
OEF/OIF combat-exposed Veterans that were eligible to participate
in the study (13 of the over 20 screened OEF/OIF Veterans) were
divided into two groups: control combat-exposed Veterans with-
out PTSD (as defined by CAPS-IV 6 35), and combat-exposed Veter-
ans with PTSD (as defined by positive DSM-IV Diagnosis, and CAPS-
IVP 60). Once enrolled into the study, blood and saliva samples
we collected from control Veterans and those with PTSD prior to
receiving any pharmacotherapy using uniform procedures for both
groups of subjects. Blood was collected into heparinized tubes. For
collection of unstimulated saliva, subjects first performed a mouth
rinse with water and, after a 10 min wait, saliva was collected by
the passive drool approach. The blood and saliva were collected
concurrently. The time of specimen collection was in the mid-
afternoon, although the precise timing was not standardized. These
blood and saliva specimens were cryopreserved until used for cyto-
kine measurements as described below.
2.3. Cytokine measurements
The blood and saliva specimens collected from OEF/OIF Veter-
ans with PTSD and OEF/OIF Veteran controls were used for mea-
surements of select Th1 stimulatory cytokines (IL-2 and IFN-c),
inflammatory cytokines (IL-6, IL-17 and TNF-a) and immune inhi-
bitory cytokines (IL-4 and IL-10). Blood specimens were cen-
trifuged for collection of plasma, while saliva was centrifuged to
remove particulate debris. Both plasma and saliva were cryopre-
served until analyzed for cytokine levels by cytokine bead array.
To measure levels of immune mediators, the frozen plasma and
saliva samples were first thawed and allowed to return to room
temperature. Levels of cytokines in plasma and saliva were then
measured using human cytometric bead array flex sets for Th1/
Th2/Th17 cytokines as directed by the manufacturer’s instructions
(BD Biosciences, San Jose, CA, USA). A FACS Canto (BD Biosciences)
flow cytometer was used to quantify cytokine profiles and relative
amounts of each cytokine were analyzed using FCAP Array Soft-
ware (manufactured by Soft Flow Hungary Ltd. for BD Biosciences,
San Jose, CA, USA). Any values that were below the level of detec-
tion by the bead array flex sets were considered as 0 values.
2.4. Statistical analyses
Data were presented as boxplots depicting the minimum, 25th,
50th (median), 75th percentiles, and maximum for cytokine levels
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mally distributed, a Mann-Whitney U test was used to determine
significance of differences in values between control versus PTSD
subjects (GraphPad Prism version 6.03 for Windows, GraphPad
Software, La Jolla, CA, USA). The Cohen’s d was used as the effect
size measure for the Student’s t test. The Spearman’s rank correla-
tion was calculated to assess the strength of the correlation
between cytokine levels in the plasma versus in the serum in sub-
jects. The Fisher’s exact test was used to determine significance of
differences in race between the groups of subjects. Significance for
all analyses was reported at the 95% confidence interval.Fig. 1. Increased levels of stimulatory and inflammatory cytokines, and reduced
levels of immune inhibitory cytokines in blood plasma of Veterans with PTSD.
Plasma levels of cytokines were measured and compared between Veterans with
PTSD or control Veterans without PTSD, both groups having similar levels of combat
exposure. Significance of the difference between plasma cytokine levels in controls
versus Veterans with PTSD were measured by the Mann Whitney U test:
= p < 0.05, = p < 0.01. The effect sizes (Cohen’s d) are as follows: IL-
2 = 4.453, IFN-c = 1.690, IL-6 = 2.605, IL-17 = 2.781, TNF-a = 2.067, IL-4 = 3.400, IL-
10 = 1.186.3. Results
3.1. Study participants
This exploratory study involving a tightly controlled and rela-
tively homogeneous group of OEF/OIF combat-exposed Veterans
compared levels of select Th1, inflammatory and inhibitory
immune mediators among control Veterans and those with PTSD.
Shown in Table 1 is a summary of the combat-exposed Veterans
whose cytokine levels were measured. A total of 13 OEF/OIF
combat-exposed Veterans were enrolled into this exploratory
study. Seven of these 13 Veterans met the full criteria for PTSD,
but had not yet received pharmacotherapy for PTSD. The remaining
6 Veterans tested negative for PTSD. As the subjects were all in
combat during their military service, the majority were males,
although the study was open to both males and females. There
were no significant differences in age or racial distribution among
Veterans without PTSD and those with PTSD. There was a signifi-
cant difference in PTSD severity between the two groups, as deter-
mine by the CAPS total score. Based on a cut-off HAM-D score of 20
to define subjects with versus without depression, 3 of the PTSD
subjects were classified as not being depressed and 4 as having
depression. However, those with active or lifetime major mental
health diagnosis or with severe traumatic brain injury were
excluded from this study. A review of the medical records of the
research subjects identified two PTSD participants and one control
participant had reported a prior history of allergic rhinitis. How-
ever, there were no other outstanding health differences, including
no other ongoing causes of inflammation and no problems associ-
ated with oral health.
3.2. Increased plasma levels of Th1 and inflammatory cytokines, and
diminished levels of immune inhibitory cytokines in combat-exposed
Veterans with PTSD
Three categories of cytokines were measured in combat-
exposed Veterans with and without PTSD: Th1, inflammatory andTable 1
Descriptive and clinical information on research subjects.
Controls PTSD p
(n = 6) (n = 7)
Age 39.0 ± 7.5 44.4 ± 9.6 NS
Males 5 (83.3%) 7 (100%) NS
Race NS
Caucasian 5 (83.3%) 4 (57.1%)
African American 0 (0.0%) 3 (42.9%)
Hispanic 1 (16.7%) 0 (0.0%)
Combat exposure severity 9.67 ± 9.09 13.43 ± 5.71 NS
PTSD severity 11.7 ± 22.8 75.9 ± 13.3 <0.0005
HAM-D 4.0 ± 6.2 22.7 ± 10.6 <0.002
Combat exposure severity = CES total score; PTSD severity = CAPS total score. The p-
values represent results of t-tests between groups except for the p-value for race,
which is the result of Fisher’s exact test.inhibitory cytokines. While limited by the low number of subjects,
results show a dysregulated immune state of OEF/OIF combat
Veterans with PTSD (Fig. 1). Subjects with PTSD had increased
plasma levels of the Th1 cytokine IL-2. Levels of the Th1 cytokine
IFN-c were elevated in subjects with PTSD, but this increase was
not statistically significant. Of the inflammatory mediators that
were measured, plasma levels of both IL-6 and IL-17 were
increased in subjects with PTSD over levels in controls. Plasma
levels of TNF-a were low in both groups of subjects, although the
levels tended to be higher in the PTSD group of subjects. In contrast
to the increases in Th1 and inflammatory cytokine levels, plasma
levels of the inhibitory mediator IL-4 were reduced in PTSD sub-
jects. IL-10, which is also an inhibitory mediator, was in lower
levels in the plasma of PTSD subjects, but the decrease was not
significant. For each of the cytokines measured, the effect size
(Cohen’s d) was large, ranging from 1.186 to 4.453, with the weak-
est being for IFN-c and IL-10, and the strongest for IL-2 and IL-4
(Fig. 1 legend). These results indicate immune imbalance inFig. 2. Increased levels of stimulatory and inflammatory cytokines, and reduced
levels of immune inhibitory cytokines in saliva of Veterans with PTSD. Levels of
cytokines in saliva were measured and compared between Veterans with PTSD or
control Veterans without PTSD, both groups having similar levels of combat
exposure. Significance of the difference between plasma cytokine levels in controls
versus Veterans with PTSD were measured by the Mann-Whitney U test:
= p < 0.05, = p < 0.01. The effect sizes (Cohen’s d) are as follows: IL-
2 = 2.752, IFN-c = 2.440, IL-6 = 5.927, IL-17 = 3.538, TNF-a = 2.312, IL-4 = 0.941, IL-
10 = 4.570.
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cytokines and a reduction in the immune inhibitory control
mediators.
3.3. Prominent increases in levels of Th1 and inflammatory cytokines
in saliva, with diminished salivary levels of inhibitory cytokines in
Veterans with PTSD
While most prior studies examining cytokine levels in subjects
with PTSD have measured levels in plasma, studies looking at
stressful events related to and unrelated to PTSD have suggested
that alterations in inflammatory cytokine levels may occur in saliva
[3,4,9,28]. In addition to measuring the more commonly measured
inflammatory cytokines, the present study also measured levels of
Th1 and inhibitory cytokines in saliva of the same subjects whose
blood plasma levels of cytokines were described above. These mea-
surements showed several similarities to what was seen in plasma
cytokine levels, but also revealed differences (Fig. 2). Consistent
with the tendency seen for cytokines in plasma, levels of Th1 and
inflammatory cytokines were all significantly increased in subjects
with PTSD compared to levels in control subjects. This included
both of the Th1 cytokines, IL-2 and IFN-c. It also included the
inflammatory cytokines, IL-6 and IL-17. While levels of TNF-awere
increased in saliva of PTSD subjects, the difference was not signif-
icant. Contrasting with these increases, levels of both of the inhibi-
tory cytokines, IL-4 and IL-10, were significantly lower in saliva of
Veterans with PTSD compared to levels in control Veterans. The
effect sizes (Cohen’s d) for differences in cytokine levels in the sal-
iva of control versus PTSD subjects were large for all measured
cytokines, ranging from 0.941 to 5.927, with the weakest being
for IL-4, and the strongest for IL-6 and IL-10 (Fig. 2 legend).
Assessment of correlation between levels of cytokines in plasma
versus saliva of each control subject showed no significant correla-
tions. In contrast, there was a strong correlation in levels of IL-6
that were present in plasma and saliva of Veterans with PTSD
(R = 0.7143). Also, there was a strong correlation in levels of the
immune inhibitory mediator IL-10 between plasma and saliva of
subjects with PTSD (R = 0.8571).
One very prominent difference between cytokine levels in
plasma and in saliva is the higher absolute level of each cytokine
in saliva of both controls as well as PTSD subjects. This is depictedFig. 3. Greater cytokine levels in saliva compared to levels in plasma in both control
and PTSD subject groups, but the increases in Th1 and inflammatory cytokines in
saliva are more prominent for PTSD subjects. The percent increase in cytokine levels
in saliva over levels in plasma were calculated from the means of the cytokine levels
for each group of subjects by the following formula: salivaplasma levelsplasma levels
h i
 100 The
significance of the difference in levels of each cytokine in plasma versus saliva was
determined by the Mann-Whitney U test: = p < 0.05, = p < 0.01;
= p < 0.005.in Fig. 3 showing the percent increases in mean salivary levels over
mean plasma levels for control Veterans without PTSD and Veter-
ans with PTSD. Also shown in this figure are the cytokines whose
levels are statistically significantly different between levels in
plasma versus saliva. Fig. 3 indicates a more prominent increase
in the Th1 and inflammatory mediators in saliva versus plasma
of subjects with PTSD compared to differences in control subjects.
It also shows the lower level of increase in inhibitory cytokines in
saliva versus plasma of Veterans with PTSD. This is more clearly
shown in Fig. 4 depicting the percent difference in the mean cyto-
kine levels in PTSD subjects over mean levels for control subjects.
This figure provides an alternate means to indicate that cytokine
levels in saliva of PTSD subjects are more prominently skewed
toward a Th1 and inflammatory phenotype. It also indicates more
prominent reduction in mean levels of immune inhibitory media-
tors in saliva versus in plasma of PTSD subjects compared to levels
in controls.
3.4. Comparison of cytokine levels among PTSD subjects with or
without depression
As depression has previously been associated with an increase
in inflammatory mediators [29,30], the contribution of depression
to the immune skewing in PTSD subjects was determined by com-
paring cytokine levels in plasma and saliva between PTSD subjects
with versus without a diagnosis of depression (HAM-DP 20).
When comparing plasma cytokine levels, there were no differences
in levels of any of the cytokines between PTSD subjects with versus
without depression (data not shown). The levels of IL-17 in saliva
of PTSD subjects with depression was slightly greater than that
for PTSD subjects without depression, but this difference was not
statistically significant (p = 0.189). Levels of the other cytokines
in saliva were similar among the two groups of PTSD subjects.
While this comparison was between subgroups of a small number
of subjects, they do not support depression as a major contributor
to the immune skewing demonstrated above in PTSD subjects.
4. Discussion
Prior studies have indicated heightened inflammatory activity
in subjects with PTSD. Such immune alterations in PTSD subjectsFig. 4. Th1 and inflammatory cytokine levels are greater and inhibitory cytokine
levels reduced in PTSD subjects compared to levels in controls, with the differences
being more prominent in saliva versus in plasma. The percent difference in cytokine
levels in subjects with PTSD over levels in controls were calculated from the means
of the cytokine levels for each group of subjects using the following formula:
PTSD levelscontrol levels
control levels
  100 The significance of the difference in levels of each
cytokine in subjects with or without PTSD was determined by the Student’s t-
test: = p < 0.05, = p < 0.01.
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tory cytokines such as IL-6 and TNF-a [4–8,31]. Very few studies
have also examined the balance between stimulatory and inhibi-
tory mediators in subjects with PTSD. A significant challenge to
studying the immune association with PTSD is the variability in
the extent and type of trauma exposure. The present study was
exploratory to test a novel approach to limit such variables so as
to more accurately visualize the immune influence of PTSD. With
that goal, this study used a tightly defined population of Veterans,
all of whom had similar levels of OEF/OIF combat exposure and all
being in good health, except some of the subjects were diagnosed
with PTSD and others were tested negative for PTSD. Also, none of
the subjects had received any pharmacotherapy for PTSD. Our
analysis of a spectrum of immune mediators showed skewing
toward Th1 and inflammatory mediators and a reduction in inhibi-
tory mediators in subjects with PTSD compared to levels in
combat-exposed Veterans without PTSD. This was seen in both
plasma and saliva, with skewing being significantly more pro-
nounced in saliva than in plasma. In the saliva, levels of each
cytokines in the Th1 and inflammatory groupings were increased
and levels of each of the inhibitory mediators were reduced in
Veterans with PTSD compared to levels in control Veterans.
Previously conducted studies that have suggested PTSD to be
associated with an inflammatory state have traditionally measured
levels of inflammatory cytokines in the blood plasma. However, the
results of the present study suggest that the altered balance among
Th1/inflammatory and inhibitory immune mediators in saliva
more prominently depicts the immune dysregulated immune state
in subjects with PTSD. It has previously been suggested that levels
of immune mediators in the saliva can be influenced by sympa-
thetic nervous system innervation, rather than being secondary
to blood levels of the mediators. This suggestion comes from
demonstrations of earlier appearance of inflammatory cytokines
in saliva following an acute stress than the increases that were
seen systemically [9,32]. Thus, salivary cytokine levels may be
more reflective of the mental health status than would plasma
cytokine levels.
Cytokine levels in plasma and saliva can be influenced by a mul-
titude of factors. While there were no noted differences in oral
health or in other health conditions between the two groups of
subjects, it is important to note that the salivary cytokine compo-
sition can be biased by the subject’s health status, including oral
health status. For example, levels of inflammatory cytokines are
increased in subjects with periodontitis [33], premalignant oral
lesions [34] or oral cancer [35]. In addition, depression has been
suggested to be associated with an inflammatory state [29,30]. This
study’s analysis of cytokine levels in PTSD subjects with or without
depression showed no significant differences in levels in either the
plasma or saliva suggesting that depression was not a significant
contributor to immune skewing associated with PTSD. While this
comparison is weakened by the low number of subjects in the sub-
groups, it is consistent with a prior study showing that the pro-
inflammatory phenotype of subjects with PTSD is independent of
depression [36].
Studies using animal models for PTSD have shown that the dys-
regulation of cytokines that is seen peripherally is also seen in
select brain regions where levels of the inflammatory mediator
IL-1 are increased, while levels of the inhibitory cytokines IL-4
and IL-10 are reduced [37]. Other animal models have shown that
induction of peripheral inflammation causes an increase in the
number of activated microglia and in levels of inflammatory medi-
ators IL-1, IL-6 and TNF-a in the hippocampus [13]. Immune-brain
communication is further intertwined such as by the trafficking of
monocytes from the periphery to the brain, resulting in the re-
establishment of anxiety in stress-sensitized mice [14]. That
immune mediators such as IL-1, IL-6, and TNF-a are able to crossthe blood-brain barrier further emphasizes how peripheral
immune reactivity can have CNS impacts [11].
Studies showing peripheral immune activation results in
inflammation in the brain further underscore their inter-
communication and its impact on behavior. For example, a popula-
tion study showed low-grade inflammation to be associated with
depressive disorder and that this was independent of other dis-
eases such as diabetes, cardiovascular disease, or kidney disease
[29]. Levels of the inflammatory markers IL-1Ra and TNF-R1 were
increased in patients with schizophrenia [38]. Inflammation asso-
ciated with viral or bacterial infectious burden was associated with
Alzheimer’s disease [39]. While none of these studies prove inflam-
mation to be responsible for mental health disorders, the associa-
tion provides support for more definitive investigations into the
pathogenic role of inflammation. Such studies are more feasible
in animal models than with human subjects. In one such study,
endotoxin-induced neuroinflammation resulted in depressive-like
behaviors [40]. In a separate study, treatment of rodents with
endotoxin induced despair-like behavior, which was shown to be
inflammation-mediated as it was abolished by treatment with
antibody against neutrophils [41].
Although this study demonstrated immune imbalances in
Veterans with PTSD, this study has weaknesses and has left sev-
eral unanswered questions. A major weakness of this study is
the limited number of subjects that were studied. As this was
an exploratory study for future analysis of cytokines or balances
in cytokine levels that might be useful as biomarkers for PTSD,
the number of subjects enrolled in this pilot study was limited.
However, despite this limitation, the study yielded statistically
significant results and clearly showed the immune dysregulation
in PTSD subjects. This may have been achieved as a result of the
study design having an emphasis on limiting variability among
study participants, which is often a challenge due to variability
in the extent and type of trauma exposure. What information
is available about health behaviors that vary as a function of
mental health (e.g., smoking status, body mass index) and that
are also reliably related to inflammation? This pertains to gen-
eral status (e.g., smoker/non-smoker) and also health behaviors
prior to saliva collection (e.g., smoking, use of caffeine, etc.). If
this information is not available, it should be addressed in the
discussion as a limitation. In future studies, the immunological
dysfunction will need to be analyzed in the context of the sub-
jects’ PTSD clinical status so as to determine if the immune
imbalances are more pronounced in subjects with more severe
PTSD or if select CAPS cluster scores more closely correlate with
the inflammatory phenotype than other cluster scores. Also
needed in future analyses is whether the immune balances are
restored with pharmacotherapy for PTSD in those patients that
are responsive or remain unresponsive to treatment. Not yet
explored are mechanisms underlying the loss of immune
regulation in PTSD subjects. Also, the alternations in signaling
pathways that allow Th1 and inflammatory mediators to be
increased and which suppress levels of inhibitory regulatory
cytokines have yet to be studied. Despite these unanswered
questions, the present study shows immune imbalances toward
an increased Th1/inflammatory state with diminished negative
controls, and a loss of coordination of levels of cytokines with
stimulatory or inhibitory activity.
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